Journal
THERAPEUTIC ADVANCES IN HEMATOLOGY
Volume 10, Issue -, Pages 1-13Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620719841735
Keywords
avatrombopag; eltrombopag; immune thrombocytopenia; ITP; platelets; romiplostim; thrombopoietin; thrombopoietin receptor agonist
Categories
Funding
- National Hemophilia Foundation-Shire Clinical Fellowship Award
Ask authors/readers for more resources
The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors commonly used to treat immune thrombocytopenia (ITP). There are three agents that have been investigated for the treatment of chronic ITP: the peptide agent romiplostim and the small molecule agents eltrombopag and avatrombopag. These agents offer a higher clinical response rate than most other ITP therapies but may require indefinite use. This review is a critical appraisal of the TPO-RAs in adult ITP, defining the optimal patient groups to receive these agents and assisting the hematologist with agent choice, goals of treatment, dosing strategies, and toxicity management. Use of endogenous thrombopoietin levels to predict response to eltrombopag and romiplostim treatment is discussed and alternative dosing protocols suited for certain patient subgroups are described. Finally, indications for discontinuation and combination therapy with other agents are considered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available